Antimicrobial Multi-Resistance of Acinetobacter baumanii Isolated from Clinical Specimens in Douala (Cameroon)
Journal of Diseases and Medicinal Plants
Volume 1, Issue 2, June 2015, Pages: 31-36
Received: May 22, 2015; Accepted: May 31, 2015; Published: Jun. 1, 2015
Views 4313      Downloads 168
Authors
Cecile Okalla Ebongue, Clinical biology Laboratory, General Hospital of Douala, Douala, Cameroon; Department of Biological Sciences, Faculty of Medicine, University of Douala, Douala, Cameroon
Emmanuel Roddy Mengue, Clinical biology Laboratory, General Hospital of Douala, Douala, Cameroon; Department of Biomedical Sciences, Faculty of Science, University of Ngaoundere, Ngaoundere, Cameroon
Jean-Pierre Nda Mefo’o, Clinical biology Laboratory, General Hospital of Douala, Douala, Cameroon; Department of Biological Sciences, Faculty of Medicine, University of Douala, Douala, Cameroon
Martial Dongmo Tsiazok, Department of Biological Sciences, Faculty of Medicine, University of Douala, Douala, Cameroon
Raymond N’guessan Kouassi, Department of Biological Sciences, Faculty of Medicine, University of Cocody, Abidjan, Ivory Cost
Elisabeth Ngo Bum, Department of Biological Sciences, Faculty of Science, University of Ngaoundere, Ngaoundere, Cameroon
Article Tools
Follow on us
Abstract
Bacteria of the genus Acinetobacter are non-fermentative gram-negative bacilli, often considered as ubiquitous and frequently found in the environment. This work aimed to study the susceptibility of Acinetobacter baumannii isolated at the General Hospital of Douala. This bacterium, which is greatly involved in human pathology, demonstrated high innate and acquired resistance to multiple antibiotics classes. This was a descriptive and retrospective study over a period of ten years (2005-2014), covering all the isolates of Acinetobacter baumannii from in and out patients. Samples were analyzed in the bacteriology laboratory at the General Hospital of Douala. Data collection was made by extraction of the results of all susceptibility of Acinetobacter baumannii, carried out from 2005 to 2014, registered in the memory of the mini API™ system; this automated machine identifies and measures the susceptibility of all the bacterial strains. A total of 266 strains were isolated from suppurations, urine, urinary catheters, and all other specimens received by the laboratory during the study period. These strains obtained from samples collected from all services of the hospital and ambulatory patients. The resistance rates noted were: 67.29 % for ticarcillin, 64.28 % ticarcillin + clavulanic acid, 68.33 % for piperacillin, 56.97 piperacillin + tazobactam, 58.27 % ceftazidime, 58.01 % cefepime, 21.05 % imipenem, 33.46 % colistin, 52.63 % gentamicin, 48.49 % tobramycin, 24.43 % amikacin, 53.40 % netilmicin, 50% for ciprofloxacin and levofloxacin, 51.05 % ofloxacin. The prevalence of multi-resistant strains was 43.18 %, mostly seen in patients hospitalized in the Burns unit. Only imipenem and Amikacin showed good activity on these strains with 78.95 % and 75.57 % of susceptibility respectively. This study showed the low activity of penicillin even in combination with beta lactamases inhibitors, as well as the cephalosporins on strains of Acinetobacter baumannii. Therapeutic support of infections due to this pathogen is highly problematic in General hospital of Douala. However, imipenem and amikacin, and to a lesser extent colistin remains effective treatment choices.
Keywords
Acinetobacter baumannii, Multi-Drug Resistance, Antibiotics, Cameroon
To cite this article
Cecile Okalla Ebongue, Emmanuel Roddy Mengue, Jean-Pierre Nda Mefo’o, Martial Dongmo Tsiazok, Raymond N’guessan Kouassi, Elisabeth Ngo Bum, Antimicrobial Multi-Resistance of Acinetobacter baumanii Isolated from Clinical Specimens in Douala (Cameroon), Journal of Diseases and Medicinal Plants. Vol. 1, No. 2, 2015, pp. 31-36. doi: 10.11648/j.jdmp.20150102.12
References
[1]
Morgan, D. J., Rogawski, E., Thom, K. A., Johnson, J. K., Perencevich, E. N., Shardell, M. , & Harris, A. D. (2012). Transfer of multidrug-resistant bacteria to healthcare workers’ gloves and gowns after patient contact increases with environmental contamination. Critical care medicine, 40(4), 1045.
[2]
Thom KA, Johnson JK, Lee MS, Harris AD. Environmental Contamination due to Multidrug-resistant Acinetobacter baumannii surrounding Colonized or Infected Patients. Am J Infect Control. 2011;39(9):711–5.
[3]
Decré, D. (2012). Acinetobacter baumannii et résistance aux antibiotiques: un modèle d’adaptation. Revue Francophone des Laboratoires, 2012(441), 43-52.
[4]
Naas, T., Coignard, B., Carbonne, A., Blanckaert, K., Bajolet, O., Bernet, C., ... & Nordmann, P. (2006). VEB-1 extended-spectrum β-lactamase–producing Acinetobacter baumannii, France. Emerging infectious diseases, 12(8), 1214.
[5]
Arsalane, L., Qamouss, Y., Chafik, A., Boughalem, M., & Louzi, L. (2010). Epidémiologie des bactéries multi résistantes dans un service de réanimation polyvalente d’un hôpital universitaire de Marrakech entre octobre 2006 et septembre 2009. Les technologies de laboratoire, 5(21).
[6]
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538–82.
[7]
Fiester, S. E., & Actis, L. A. (2013). Stress responses in the opportunistic pathogen Acinetobacter baumannii. Future microbiology, 8(3), 353-365.
[8]
Gupta, V., Garg, R., Garg, S., Chander, J., & Attri, A. K. (2013). Coexistence of extended spectrum beta-lactamases, AmpC beta-lactamases and metallo-beta-lactamases in Acinetobacter baumannii from burns patients: a report from a tertiary care centre of India. Annals of burns and fire disasters, 26(4), 189.
[9]
Bonomo, R. A., & Szabo, D. (2006). Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clinical Infectious Diseases, 43(Supplement 2), S49-S56.
[10]
Nicolay, N., Thiolet, J. M., Talon, D., Poujol, I., Bernet, C., Carbonne, A., ... & Coignard, B. (2008). Signalement des infections nosocomiales à Pseudomonas aeruginosa, France, Août 2001-Juin 2006. Bull Epidemiol Hebd, 30-31.
[11]
Sunenshine, R. H., Wright, M. O., Maragakis, L. L., Harris, A. D., Song, X., Hebden, J., ... & Srinivasan, A. (2007). Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerging infectious diseases, 13(1), 97.
[12]
Lee, Y. T., Kuo, S. C., Yang, S. P., Lin, Y. T., Tseng, F. C., Chen, T. L., & Fung, C. P. (2012). Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clinical infectious diseases, 55(2), 209-215.
[13]
Soussy CJ. Comité d'antibiogramme de la société francaise de microbiologie: récommandation 2011. 2011.
[14]
Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., ... & Monnet, D. L. (2012). Multidrug‐resistant, extensively drug‐resistant and pandrug‐resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection, 18(3), 268-281.
[15]
Memish, Z. A., Shibl, A. M., Kambal, A. M., Ohaly, Y. A., Ishaq, A., & Livermore, D. M. (2012). Antimicrobial resistance among non-fermenting Gram-negative bacteria in Saudi Arabia. Journal of antimicrobial chemotherapy, 67(7), 1701-1705.
[16]
Patel, P. H., Pethani, J. D., Rathod, S. D., Chauhan, B., & Shah, P. D. (2013). Prevalence of nonfermenting Gram negative bacilli infection in tertiary care Hospital in Ahmedabad, Gujarat. Indian Journal of Basic & Applied Medical Research, 2(6), 608-613.
[17]
Njall, C., Adiogo, D., Bita, A., Ateba, N., Sume, G., Kollo, B., ... & Tchoua, R. (2013). Écologie bactérienne de l'infection nosocomiale au service de réanimation de l'hôpital Laquintinie de Douala, Cameroun. The Pan African Medical Journal, 14.
[18]
Réseau, R. E. A. Raisin. Surveillance des infections nosocomiales en réanimation adulte: Résultats 200 France: Institut de veille sanitaire, sept. 2009; 60p. PubMed| Google Scholar.
[19]
Ahoyo, T. A., Bankolé, H. S., Adéoti, F. M., Gbohoun, A. A., Assavèdo, S., Amoussou-Guénou, M., ... & Pittet, D. (2014). Prevalence of nosocomial infections and anti-infective therapy in Benin: results of the first nationwide survey in 2012. Antimicrobial resistance and infection control, 3(1), 1-6.
[20]
Andriamanantena, T. S., Ratsima, E., Rakotonirina, H. C., Randrianirina, F., Ramparany, L., Carod, J. F., ... & Talarmin, A. (2010). Dissemination of multidrug resistant Acinetobacter baumannii in various hospitals of Antananarivo Madagascar. Annals of clinical microbiology and antimicrobials, 9(1), 17.
[21]
Kuo, S. C., Chang, S. C., Wang, H. Y., Lai, J. F., Chen, P. C., Shiau, Y. R., ... & Lauderdale, T. L. Y. (2012). Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC infectious diseases, 12(1), 200.
[22]
Begum, S., Hasan, F., Hussain, S., & Shah, A. A. (2013). Prevalence of multi drug resistant Acinetobacter baumannii in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan. Pakistan journal of medical sciences, 29(5), 1253.
[23]
Krcmery, V., & Kalavsky, E. (2007). Multidrug-resistant Acinetobacter baumannii. Emerging infectious diseases, 13(6), 943.
[24]
Capone, A., D’Arezzo, S., Visca, P., & Petrosillo, N. (2008). In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii. Journal of antimicrobial chemotherapy, 62(2), 422-423.
[25]
Dent, L. L., Marshall, D. R., Pratap, S., & Hulette, R. B. (2010). Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC infectious diseases, 10(1), 196.
[26]
Gangoue-Pieboji, J., Koulla-Shiro, S., Ngassam, P., Adiogo, D., & Ndumbe, P. (2007). Antimicrobial activity against gram negative bacilli from Yaounde Central Hospital, Cameroon. African health sciences, 6(4).
[27]
Soraa N, Zougaghi L, Zahlane K, Admou B, Haouach K, Kachach M, et al. Épidémiologie et profil de sensibilité des isolats d'hémoculture dans un Centre Hospitalo Universitaire Marocain. Revue Tunisienne d’Infectiologie. 2011;5(2):78 - 81.
[28]
Haj Khalifa AB, Khedher M. Fréquence et profil de sensibilité aux antibiotiques des bactéries isolées des hémocultures au CHU de Mahdia. Revue Tunisienne d’Infectiologie. 2010;4(3):92 - 5.
[29]
Jans B, Glupczynski Y. Enquête épidémiologique sur Acinetobacter baumannii et Pseudomonas aeruginosa dans les hôpitaux aigus en Belgique : Données pour l'année 2008. In: d’Epidémiologie ISdSPS, editor. 14, rue Juliette Wytsman 1050 Bruxelles – Belgique: Jans Béatrice; 2009.
[30]
Xu, T., Xia, W., Rong, G., Pan, S., Huang, P., & Gu, B. (2013). A 4-year surveillance of antimicrobial resistance patterns of Acinetobacter baumanni in a university-affiliated hospital in China. Journal of thoracic disease, 5(4), 506.
[31]
Landman, D., Bratu, S., Kochar, S., Panwar, M., Trehan, M., Doymaz, M., & Quale, J. (2007). Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. Journal of antimicrobial chemotherapy, 60(1), 78-82.
[32]
Ahmed, N. H., Baba, K., Clay, C., Lekalakala, R., & Hoosen, A. A. (2012). In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa. BMC research notes, 5(1), 215.
[33]
Mansouri, S., Razavi, M., Norouzi, F., & Najar, S. G. (2012). Prevalence of β-Lactamase Production and Antimicrobial Susceptibility of Multidrug Resistant Clinical Isolates of Non-Fermenting Gram Negative Bacteria From Hospitalized Patients in Kerman/Iran. Jundishapur Journal of Microbiology, 2012(2, Spring), 405-410.
[34]
Bayram, A., & Balci, I. (2006). Patterns of antimicrobial resistance in a surgical intensive care unit of a university hospital in Turkey. BMC infectious diseases, 6(1), 155.
[35]
Vala, M. H., Hallajzadeh, M., Fallah, F., Hashemi, A., & Goudarzi, H. (2013). Characterization of the Extended-Spectrum beta-Lactamase Producers among Non-Fermenting Gram-Negative Bacteria Isolated from Burnt Patients. Archives of Hygiene Sciences, 2(1).
[36]
Guembe, E., Mansilla, E. C., Alcalá, L., Soria, R. I., Bouza, E., & Marín, M. (2008). Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003-2007. Revista Española de Quimioterapia, 21(3), 166-173.
[37]
Baadani, A. M., Thawadi, S. I., El-Khizzi, N. A., & Omrani, A. S. (2013). Prevalence of colistin and tigecycline resistance in Acinetobacter baumannii clinical isolates from 2 hospitals in Riyadh Region over a 2-year period. Saudi medical journal, 34(3), 248-253.
[38]
Morfin-Otero, R., Tinoco-Favila, J. C., Sader, H. S., Salcido-Gutierrez, L., Perez-Gomez, H. R., Gonzalez-Diaz, E., ... & Rodriguez-Noriega, E. (2012). Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005–2010. BMC research notes, 5(1), 277.
[39]
Koomanachai, P., Tiengrim, S., Kiratisin, P., & Thamlikitkul, V. (2007). Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. International Journal of Infectious Diseases, 11(5), 402-406.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186